Sitao Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sitao Xie has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Weihong Tan
Department of Biliary-Pancreatic Surgery, Institute of Molecular Medicine (IMM), Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
7 shared publications Wenxi Wang
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, PR China
6 shared publicationsYu Zhang
Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
5 shared publicationsChao Zuo
Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
4 shared publicationsKedan Gu
Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
4 shared publicationsLuting Hu
Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
4 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Genetically engineered RNA inducers of proximity for protein regulation
- 6 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessGenetically engineered RNA inducers of proximity for protein regulation
- Open Access
- 24 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy
Therapeutic strategies for peritoneal metastasis in solid tumors are urgently needed. Programming chimeric antigen receptor macrophages (CAR-Ms) in situ offers opportunities for an unmet demand. However, potential intracellular domains (ICDs) for CAR design and their antitumor mechanisms for macrophage empowerment remain to be explored systematically. By developing a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) system, we evaluate 36 CAR formats in CAR-Ms. Tailored CAR-Ms with CD3ζ TLR4 ICDs elicit robust adaptive immune activation and significantly synergize with PD-1/L1 therapy. Single-cell RNA sequencing (scRNA-seq) reveals that CAR-Ms reshape the immunosuppressive tumor microenvironment (TME) and boost the TCF1+PD-1+ progenitor-exhausted CD8+ T cells (Tpex) population. Mechanistically, CAR-Ms maintain a proinflammatory phenotype and simultaneously upregulate MHC-I and PD-L1 by perturbing NF-κB pathways. Collectively, this approach enables intraperitoneal programming of tailored CAR-Ms and broadens understanding of both regulatory and feedback mechanisms for CAR-M therapies against solid tumors.
- 24 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIntraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy
Therapeutic strategies for peritoneal metastasis in solid tumors are urgently needed. Programming chimeric antigen receptor macrophages (CAR-Ms) in situ offers opportunities for an unmet demand. However, potential intracellular domains (ICDs) for CAR design and their antitumor mechanisms for macrophage empowerment remain to be explored systematically. By developing a macrophage-targeted mRNA lipid nanoparticle (mRNA-LNP) system, we evaluate 36 CAR formats in CAR-Ms. Tailored CAR-Ms with CD3ζ TLR4 ICDs elicit robust adaptive immune activation and significantly synergize with PD-1/L1 therapy. Single-cell RNA sequencing (scRNA-seq) reveals that CAR-Ms reshape the immunosuppressive tumor microenvironment (TME) and boost the TCF1+PD-1+ progenitor-exhausted CD8+ T cells (Tpex) population. Mechanistically, CAR-Ms maintain a proinflammatory phenotype and simultaneously upregulate MHC-I and PD-L1 by perturbing NF-κB pathways. Collectively, this approach enables intraperitoneal programming of tailored CAR-Ms and broadens understanding of both regulatory and feedback mechanisms for CAR-M therapies against solid tumors.
- 17 November 2025
- Published by Springer Nature in Science China Chemistry
- Vol. 68 (12) , 6439-6442
Screening of short-chain IRES elements for enhanced circRNA translation efficiency
- 17 November 2025
- Published by Springer Nature in Science China Chemistry
- Vol. 68 (12) , 6439-6442
Screening of short-chain IRES elements for enhanced circRNA translation efficiency
- Open Access
Programmable Aptamer-Embedded Circular RNAs for Targeted Antigen-Presenting Cells Immunotherapy
The targeted delivery of mRNA to specific cell types in vivo remains a major unmet need in mRNA-based therapeutics. Conventional strategies rely on nanocarriers engineered with various modifications. However, these exogenous materials could cause adverse reactions, and their complex manufacturing processes often hinder clinical application. By leveraging the innate programmability of RNA sequences, we herein report a carrier-free, scalable, and programmable aptamer-embedded circular RNAs (Apt-circRNAs) design that confers targeting capability through the strategic incorporation of different aptamers at varying densities, while retaining circular RNA stability and protein production capability. Experimental results show that antigen-loaded Apt-circRNAs enable targeted delivery to antigen-presenting cells (APCs), drive endogenous antigen expression, activate antigen-specific T cells, and elicit potent immune responses that mediate clearance of both early-and late-stage tumors in mouse models. In humanized models of colorectal cancer, the combination of Apt-circRNA and PD-1 blockade produced synergistic antitumor effects and significantly reshaped the tumor microenvironment. In a first-in-human (FIH) clinical trial, Apt-circRNA vaccine encoding KRAS G12D/G12V neoantigens exhibited a favorable safety profile and induced robust immune activation, T cell mobilization, and neoantigen-specific immune responses. With this study, we have established a new paradigm in carrier-free, APC-targeted RNA vaccine design, offering a safe and effective platform for next-generation cancer immunotherapy.
Open AccessProgrammable Aptamer-Embedded Circular RNAs for Targeted Antigen-Presenting Cells Immunotherapy
The targeted delivery of mRNA to specific cell types in vivo remains a major unmet need in mRNA-based therapeutics. Conventional strategies rely on nanocarriers engineered with various modifications. However, these exogenous materials could cause adverse reactions, and their complex manufacturing processes often hinder clinical application. By leveraging the innate programmability of RNA sequences, we herein report a carrier-free, scalable, and programmable aptamer-embedded circular RNAs (Apt-circRNAs) design that confers targeting capability through the strategic incorporation of different aptamers at varying densities, while retaining circular RNA stability and protein production capability. Experimental results show that antigen-loaded Apt-circRNAs enable targeted delivery to antigen-presenting cells (APCs), drive endogenous antigen expression, activate antigen-specific T cells, and elicit potent immune responses that mediate clearance of both early-and late-stage tumors in mouse models. In humanized models of colorectal cancer, the combination of Apt-circRNA and PD-1 blockade produced synergistic antitumor effects and significantly reshaped the tumor microenvironment. In a first-in-human (FIH) clinical trial, Apt-circRNA vaccine encoding KRAS G12D/G12V neoantigens exhibited a favorable safety profile and induced robust immune activation, T cell mobilization, and neoantigen-specific immune responses. With this study, we have established a new paradigm in carrier-free, APC-targeted RNA vaccine design, offering a safe and effective platform for next-generation cancer immunotherapy.
- Open Access
- 7 March 2025
- Published by Springer Nature in Research Square
Intraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapy
Therapeutic strategies for peritoneal metastasis in solid tumors are urgently needed in the clinic. Programming chimeric antigen receptor macrophages (CAR-Ms) in situ offers opportunities for an unmet demand. However, potential intracellular domains (ICDs) for CAR design and their antitumor mechanisms for macrophage empowerment remain to be explored systematically. By developing a targeted mRNA-LNP delivery system for macrophages, we have investigated 36 CAR combinations to determine the impact of CAR-Ms on immune regulation in vitro and in vivo . In two solid tumor mouse models, intraperitoneal programming of CAR-Ms was shown to elicit robust adaptive immune activation and significantly synergize with PD-1/L1 therapy. Single-cell RNA sequencing (scRNA-seq) analysis revealed that CAR-Ms could reshape the immunosuppressive tumor microenvironment (TME) and boost the TCF1 + PD-1 + progenitor-exhausted CD8 + T cells (Tpex) population. Meanwhile, we found that tailored CAR-M with CD3ζ/TLR4 ICDs could favorably maintain proinflammatory phenotype and simultaneously upregulate MHC I and PD-L1 expression by perturbing NF-κB pathways. Moreover, the synergism between macrophage PD-L1 knockdown and CAR-M therapy highlighted the need to block the PD-1/L1 axis in antigen cross-presentation. In short, we developed an mRNA-LNP delivery system for intraperitoneal programming of tailored CAR-Ms in vivo and broadened understanding of both regulatory and feedback mechanisms for CAR-M therapies against solid tumors.
- 7 March 2025
- Published by Springer Nature in Research Square
Open AccessIntraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapy
Therapeutic strategies for peritoneal metastasis in solid tumors are urgently needed in the clinic. Programming chimeric antigen receptor macrophages (CAR-Ms) in situ offers opportunities for an unmet demand. However, potential intracellular domains (ICDs) for CAR design and their antitumor mechanisms for macrophage empowerment remain to be explored systematically. By developing a targeted mRNA-LNP delivery system for macrophages, we have investigated 36 CAR combinations to determine the impact of CAR-Ms on immune regulation in vitro and in vivo . In two solid tumor mouse models, intraperitoneal programming of CAR-Ms was shown to elicit robust adaptive immune activation and significantly synergize with PD-1/L1 therapy. Single-cell RNA sequencing (scRNA-seq) analysis revealed that CAR-Ms could reshape the immunosuppressive tumor microenvironment (TME) and boost the TCF1 + PD-1 + progenitor-exhausted CD8 + T cells (Tpex) population. Meanwhile, we found that tailored CAR-M with CD3ζ/TLR4 ICDs could favorably maintain proinflammatory phenotype and simultaneously upregulate MHC I and PD-L1 expression by perturbing NF-κB pathways. Moreover, the synergism between macrophage PD-L1 knockdown and CAR-M therapy highlighted the need to block the PD-1/L1 axis in antigen cross-presentation. In short, we developed an mRNA-LNP delivery system for intraperitoneal programming of tailored CAR-Ms in vivo and broadened understanding of both regulatory and feedback mechanisms for CAR-M therapies against solid tumors.
- Open Access
Intraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapy
Therapeutic strategies for peritoneal metastasis in solid tumors are urgently needed in the clinic. Programming chimeric antigen receptor macrophages (CAR-Ms) in situ offers opportunities for an unmet demand. However, potential intracellular domains (ICDs) for CAR design and their antitumor mechanisms for macrophage empowerment remain to be explored systematically. By developing a targeted mRNA-LNP delivery system for macrophages, we have investigated 36 CAR combinations to determine the impact of CAR-Ms on immune regulation in vitro and in vivo . In two solid tumor mouse models, intraperitoneal programming of CAR-Ms was shown to elicit robust adaptive immune activation and significantly synergize with PD-1/L1 therapy. Single-cell RNA sequencing (scRNA-seq) analysis revealed that CAR-Ms could reshape the immunosuppressive tumor microenvironment (TME) and boost the TCF1 + PD-1 + progenitor- exhausted CD8 + T cells (Tpex) population. Meanwhile, we found that tailored CAR-M with CD3ζ/TLR4 ICDs could favorably maintain proinflammatory phenotype and simultaneously upregulate MHC I and PD-L1 expression by perturbing NF-κB pathways. Moreover, the synergism between macrophage PD-L1 knockdown and CAR-M therapy highlighted the need to block the PD-1/L1 axis in antigen cross-presentation. In short, we developed an mRNA-LNP delivery system for intraperitoneal programming of tailored CAR-Ms in vivo and broadened understanding of both regulatory and feedback mechanisms for CAR-M therapies against solid tumors.
Open AccessIntraperitoneal programming of tailored CAR macrophages via mRNA-LNP to boost cancer immunotherapy
Therapeutic strategies for peritoneal metastasis in solid tumors are urgently needed in the clinic. Programming chimeric antigen receptor macrophages (CAR-Ms) in situ offers opportunities for an unmet demand. However, potential intracellular domains (ICDs) for CAR design and their antitumor mechanisms for macrophage empowerment remain to be explored systematically. By developing a targeted mRNA-LNP delivery system for macrophages, we have investigated 36 CAR combinations to determine the impact of CAR-Ms on immune regulation in vitro and in vivo . In two solid tumor mouse models, intraperitoneal programming of CAR-Ms was shown to elicit robust adaptive immune activation and significantly synergize with PD-1/L1 therapy. Single-cell RNA sequencing (scRNA-seq) analysis revealed that CAR-Ms could reshape the immunosuppressive tumor microenvironment (TME) and boost the TCF1 + PD-1 + progenitor- exhausted CD8 + T cells (Tpex) population. Meanwhile, we found that tailored CAR-M with CD3ζ/TLR4 ICDs could favorably maintain proinflammatory phenotype and simultaneously upregulate MHC I and PD-L1 expression by perturbing NF-κB pathways. Moreover, the synergism between macrophage PD-L1 knockdown and CAR-M therapy highlighted the need to block the PD-1/L1 axis in antigen cross-presentation. In short, we developed an mRNA-LNP delivery system for intraperitoneal programming of tailored CAR-Ms in vivo and broadened understanding of both regulatory and feedback mechanisms for CAR-M therapies against solid tumors.
- Open Access
- 1 January 2024
- Published by Science Exploration Press in BME Horizon
- Vol. 4 (3) , 202601
Macrophage-targeted mRNA therapeutics: Emerging strategies for cancer immunotherapy
Tumor-associated macrophages (TAMs) are pivotal regulators of the immunosuppressive tumor microenvironment and major contributors to resistance against conventional and immunotherapeutic interventions. Rather than eliminating TAMs, emerging strategies aim to functionally reprogram them toward an antitumor phenotype, a therapeutic objective uniquely enabled by the precise, transient, and non-integrating nature of mRNA, which allows reversible modulation without genomic risk. Recent progress in nanocarrier design has improved selective delivery to TAMs through both passive uptake and active targeting, with administration routes tailored to tumor location. Precise immunomodulatory interventions in macrophages, accomplished by mRNA payloads designed to induce pro-inflammatory polarization, enhance phagocytosis, or block immunosuppressive signals, thereby remodel the tumor immune microenvironment and generate synergy with established treatments. Future efforts might concentrate on macrophage heterogeneity, carrier immunogenicity, and scalable formulation development to advance clinical translation, not only in cancer but also in other diseases shaped by dysregulated macrophage function.
- 1 January 2024
- Published by Science Exploration Press in BME Horizon
- Vol. 4 (3) , 202601
Open AccessMacrophage-targeted mRNA therapeutics: Emerging strategies for cancer immunotherapy
Tumor-associated macrophages (TAMs) are pivotal regulators of the immunosuppressive tumor microenvironment and major contributors to resistance against conventional and immunotherapeutic interventions. Rather than eliminating TAMs, emerging strategies aim to functionally reprogram them toward an antitumor phenotype, a therapeutic objective uniquely enabled by the precise, transient, and non-integrating nature of mRNA, which allows reversible modulation without genomic risk. Recent progress in nanocarrier design has improved selective delivery to TAMs through both passive uptake and active targeting, with administration routes tailored to tumor location. Precise immunomodulatory interventions in macrophages, accomplished by mRNA payloads designed to induce pro-inflammatory polarization, enhance phagocytosis, or block immunosuppressive signals, thereby remodel the tumor immune microenvironment and generate synergy with established treatments. Future efforts might concentrate on macrophage heterogeneity, carrier immunogenicity, and scalable formulation development to advance clinical translation, not only in cancer but also in other diseases shaped by dysregulated macrophage function.
- 28 April 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (23)
X‐Ray‐triggered Carbon Monoxide and Manganese Dioxide Generation based on Scintillating Nanoparticles for Cascade Cancer Radiosensitization
Carbon monoxide (CO) is an endogenous signaling molecule with broad therapeutic effects. Here, a multifunctional X‐ray‐triggered carbon monoxide (CO) and manganese dioxide (MnO2) generation nanoplatform based on metal carbonyl and scintillating nanoparticles (SCNPs) is reported. Attributed to the radioluminescent characteristic of SCNPs, UV‐responsive Mn2(CO)10 is not only indirectly activated to release CO by X‐ray but can also be degraded into MnO2. A high dose of CO can be used as a glycolytic inhibitor for tumor suppression; it will also sensitize tumor cells to radiotherapy. Meanwhile MnO2, as the photolytic byproduct of Mn2(CO)10, has both glutathione (GSH) depletion and Fenton‐like Mn2+ delivery properties to produce highly toxic hydroxyl radical (⋅OH) in tumors. Thus, this strategy can realize X‐ray‐activated CO release, GSH depletion, and ⋅OH generation for cascade cancer radiosensitization. Furthermore, X‐ray‐activated Mn2+ in vivo demonstrates an MRI contrast effect, making it a potential theranostic nanoplatform.
- 28 April 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (23)
X‐Ray‐triggered Carbon Monoxide and Manganese Dioxide Generation based on Scintillating Nanoparticles for Cascade Cancer Radiosensitization
Carbon monoxide (CO) is an endogenous signaling molecule with broad therapeutic effects. Here, a multifunctional X‐ray‐triggered carbon monoxide (CO) and manganese dioxide (MnO2) generation nanoplatform based on metal carbonyl and scintillating nanoparticles (SCNPs) is reported. Attributed to the radioluminescent characteristic of SCNPs, UV‐responsive Mn2(CO)10 is not only indirectly activated to release CO by X‐ray but can also be degraded into MnO2. A high dose of CO can be used as a glycolytic inhibitor for tumor suppression; it will also sensitize tumor cells to radiotherapy. Meanwhile MnO2, as the photolytic byproduct of Mn2(CO)10, has both glutathione (GSH) depletion and Fenton‐like Mn2+ delivery properties to produce highly toxic hydroxyl radical (⋅OH) in tumors. Thus, this strategy can realize X‐ray‐activated CO release, GSH depletion, and ⋅OH generation for cascade cancer radiosensitization. Furthermore, X‐ray‐activated Mn2+ in vivo demonstrates an MRI contrast effect, making it a potential theranostic nanoplatform.
- 28 April 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (23) , e202302525
X‐Ray‐triggered Carbon Monoxide and Manganese Dioxide Generation based on Scintillating Nanoparticles for Cascade Cancer Radiosensitization
Carbon monoxide (CO) is an endogenous signaling molecule with broad therapeutic effects. Here, a multifunctional X‐ray‐triggered carbon monoxide (CO) and manganese dioxide (MnO2) generation nanoplatform based on metal carbonyl and scintillating nanoparticles (SCNPs) is reported. Attributed to the radioluminescent characteristic of SCNPs, UV‐responsive Mn2(CO)10 is not only indirectly activated to release CO by X‐ray but can also be degraded into MnO2. A high dose of CO can be used as a glycolytic inhibitor for tumor suppression; it will also sensitize tumor cells to radiotherapy. Meanwhile MnO2, as the photolytic byproduct of Mn2(CO)10, has both glutathione (GSH) depletion and Fenton‐like Mn2+ delivery properties to produce highly toxic hydroxyl radical (⋅OH) in tumors. Thus, this strategy can realize X‐ray‐activated CO release, GSH depletion, and ⋅OH generation for cascade cancer radiosensitization. Furthermore, X‐ray‐activated Mn2+ in vivo demonstrates an MRI contrast effect, making it a potential theranostic nanoplatform.
- 28 April 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (23) , e202302525
X‐Ray‐triggered Carbon Monoxide and Manganese Dioxide Generation based on Scintillating Nanoparticles for Cascade Cancer Radiosensitization
Carbon monoxide (CO) is an endogenous signaling molecule with broad therapeutic effects. Here, a multifunctional X‐ray‐triggered carbon monoxide (CO) and manganese dioxide (MnO2) generation nanoplatform based on metal carbonyl and scintillating nanoparticles (SCNPs) is reported. Attributed to the radioluminescent characteristic of SCNPs, UV‐responsive Mn2(CO)10 is not only indirectly activated to release CO by X‐ray but can also be degraded into MnO2. A high dose of CO can be used as a glycolytic inhibitor for tumor suppression; it will also sensitize tumor cells to radiotherapy. Meanwhile MnO2, as the photolytic byproduct of Mn2(CO)10, has both glutathione (GSH) depletion and Fenton‐like Mn2+ delivery properties to produce highly toxic hydroxyl radical (⋅OH) in tumors. Thus, this strategy can realize X‐ray‐activated CO release, GSH depletion, and ⋅OH generation for cascade cancer radiosensitization. Furthermore, X‐ray‐activated Mn2+ in vivo demonstrates an MRI contrast effect, making it a potential theranostic nanoplatform.